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Purpose. To report the long-term follow-up results in patients with cataract and primary open-angle glaucoma (POAG) randomly
assigned to cataract surgery combined with micro-bypass stent implantation or phacoemulsification alone. Methods. 36 subjects
with cataract and POAG were randomized in a 1 : 2 ratio to either iStent implantation and cataract surgery (combined group) or
cataract surgery alone (control group). 24 subjects agreed to be evaluated again 48 months after surgery. Patients returned one
month later for unmedicated washout assessment. Results. At the long-term follow-up visit we reported a mean IOP of 15,9 ±
2,3mmHg in the iStent group and 17 ± 2,5mmHg in the control group (𝑝 = NS). After washout, a 14,2% between group difference
in favour of the combined groupwas statistically significant (𝑝 = 0, 02) formean IOP reduction. A significant reduction in themean
number of medications was observed in both groups compared to baseline values (𝑝 = 0, 005 in the combined group and 𝑝 = 0, 01
in the control group). Conclusion. Patients in the combined group maintained low IOP levels after long-term follow-up. Cataract
surgery alone showed a loss of efficacy in controlling IOP over time. Both treatments reduced the number of ocular hypotensive
medications prescribed. This trial is registered with: NCT00847158.
1. Introduction
Primary open-angle glaucoma (POAG) accounts for at least
90% of all glaucoma cases and affects primarily 3 million
people in the United States. Cedrone et al. reported a 3,2%
incidence of POAG in the population-based Ponza eye study
[1]. Increased intraocular pressure (IOP) in POAG is due
to progressive obstruction of drainage which may lead to
the damage of the optic nerve and subsequently blindness,
if left untreated. Moreover, glaucoma and cataract incidence
increasewith age and are frequently found in the same patient
[2, 3]. Thus, cataract surgery may be a good management
option in medically controlled nonsevere glaucoma with a
mild reduction in IOP [4, 5].
The iStent (Glaukos Corporation, Laguna Hills, CA) was
developed to bypass the trabecular meshwork and create a
direct route from the anterior chamber to Schlemm’s canal.
This ab interno device is implanted using the same temporal
clear corneal incision used for cataract surgery.The iStent has
been shown to lower IOP while reducing ocular hypotensive
medication usage in prior studies involving eyes randomly
assigned to cataract surgery and iStent implantation or
cataract surgery alone with follow-up through 1 year to
24 months [6–9]. We reported in a previous study our
findings involving subjects with POAG randomly assigned
to phacoemulsification with micro-bypass stent implantation
or phacoemulsification alone with a follow-up of 16 months
[6]. IOP was statistically significantly lower in the combined
group both before and after washout as compared to the
control group. In addition, the mean number of medications
was significantly lower in the combined group versus the
control group. The purpose of this recent work was to report
on long-term results through a minimum of 4 years on the
original cohort of subjects.
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2. Materials and Methods
2.1. Subjects and iStent. This prospective randomized study
comprised 36 subjects with cataract and POAG. Subjects
were required to have an IOP > 18mmHg in three different
visits while using at least one ocular hypotensive medication
and a corrected distance visual acuity worse than 20/80.
Key exclusion criteria were glaucoma other than POAG,
cloudy cornea, potentially inhibiting gonioscopic view of the
angle, peripheral anterior synechiae, prior ocular surgery,
diabetic retinopathy, and age-related macular degeneration.
Subjects were randomized in a 1 : 2 ratio to either iStent
implantation in conjunctionwith cataract surgery (combined
group) or cataract surgery alone (control group). The micro-
bypass iStent (Glaukos Corporation, Laguna Hills, CA) is
a heparin-coated L-shaped device (Duraflo, Edwards Life-
sciences, Irvine, CA) made from titanium with a length of
1.0mm and height of 0.33mm and snorkel with a diameter
of approximately 120𝜇m. When implanted, the snorkel is
located in the anterior chamber and the open half-pipe lumen
(foot) is located in Schlemm’s canal. This ab interno device
establishes a patent bypass through the trabecular meshwork
to Schlemm’s canal to restore continuous physiologic outflow.
2.2. Surgical Technique. All subjects underwent standard
clear corneal phacoemulsification with IOL implantation [6].
All preoperative peribulbar anesthesia dosing was considered
current standard of care. Subjects implanted with the iStent
(combined group) underwent stent implantation after IOL
implantation.The stent was guided into the canal of Schlemm
by ab interno gonioscopy using a Swan-Jacobs gonioscope.
If no complications occurred during phacoemulsification,
acetylcholine was injected into the anterior chamber after
IOL implantation to constrict the pupil.The anterior chamber
was then filled with an ophthalmic viscosurgical device to
reform the anterior chamber and provide more clearance in
the angle. With the stent on the tip of the applicator, the
anterior chamber was traversed with the applicator and the
trabecular meshwork located. The leading edge of the stent
was gently slid through the trabecular meshwork and into the
canal of Schlemm at the nasal position (3 to 4 o’clock in right
eye; 9 to 8 o’clock in left eye) with the tip of the stent directed
inferiorly. If there was difficulty with insertion at the primary
location, a location of approximately 0.5 o’clock inferiorly was
attempted and the surgeon continued to move inferiorly as
needed for subsequent attempts. Next, the stent was released
by pushing the button on the applicator. After the position of
the stent was verified, the applicator was withdrawn.
2.3. Postoperative Follow-Up. Following the postoperative
course described in the original paper, subjects were con-
tacted again after approximately 4 years to determine their
availability and willingness to undergo participation in a
follow-up evaluation [6]. A total of 24 subjects agreed to
participate. Subjects underwent an initial long-term eval-
uation, at which time they were instructed to discontinue
ocular hypotensive medication and return 1 month later for
an unmedicated assessment (washout evaluation).
2.4. Statistical Analysis. The efficacy analysis comprises all
available long-term data on medicated IOP, ocular hypoten-
sive medication use, and postmedication washout IOP. For
continuous variables, 2-sample 𝑡-tests were used to assess
between-group differences. Fisher exact tests were used to
compare categorical outcomes between groups. An 𝛼 level of
0,05was considered statistically significant. All statistical tests
were performed using PC-SAS (Version 9.1.3).
3. Results and Discussion
3.1. Patients Demographics. Of the original cohort of 36
randomized subjects, 24 subjects were available for long-term
follow-up assessment. A total of 5 subjects died, 5 subjects
were lost to follow-up, one subject refused washout, and one
subject could not travel to the clinic (Figure 1).
3.2. Intraocular Pressure. At baseline, mean IOP was 17,8 ±
2,7mmHg in the combined group and 16,7 ± 3mmHg in the
control group (Table 1).
This difference was not statistically significant (𝑝 = NS).
At the month 12 visit after washout, mean IOP was 16,1 ±
2mmHg and 18,4 ± 3,1mmHg in the iStent and the control
group, respectively, a difference that was statistically signif-
icant (𝑝 = 0,05). Long-term follow-up visit before washout
reported a mean IOP of 15,9 ± 2,3mmHg in the iStent group
and 17 ± 2,5mmHg in the control group (𝑝 = NS). After
the washout the IOP was 17,5 ± 2,3mmHg in the combined
group versus 20,4 ± 3,2mmHg in the control group. In
the combined group we found no statistically significant
difference between before and after washout (𝑝 = 0,14) while
it was found in the control group (𝑝 = 0.04). At the long-term
follow-up visit after washout we found a difference of 14,2%
between groups formean IOP reduction (𝑝=0,02) (Figure 2).
The difference between baseline and after washout IOP was
0,3mmHg in the combined group versus 3,7mmHg in the
control group.
3.3. Ocular Hypotensive Medications. At baseline, the mean
number of ocular hypotensive medications used was 1,9 ± 0,9
in the combined group and 1,8 ± 0,7 in the control group, a
difference that was not statistically significant (𝑝 = NS). At 12
months, themean number ofmedications was 0,4 ± 0,7 in the
treatment group and 1 ± 1 in the control group (Table 2).
These reductions were statistically significant compared
to baseline values (𝑝 = 0,003 for treatment group and 𝑝 = 0,01
for the control group).
At long-term follow-up patients in the combined group
used 0,5 ± 0,8 medications, a difference statistically signifi-
cant compared to baseline (𝑝 = 0,005). Patients in the control
group also had a significant reduction in the mean number
of ocular hypotensive medications used (0,9 ± 1 medications;
𝑝 = 0,01). No statistically significant difference was reported
between groups at any visit.
3.4. Safety. The majority of patients had an improvement of
UDVA and CDVA after phacoemulsification and intraocular
lens (IOL) implantation. No significant differences were
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Total
36 eyes
Combined group
(stent + phacoemulsification)
12 eyes
n = 1 lost to follow-up
n = 1 refused washout
Long-term data
10 eyes
Control group
Phacoemulsification
24 eyes
n = 5 died
n = 4 lost to follow-up
n = 1 unable to visit the clinic
Long-term data
14 eyes
Figure 1: Subject accountability: a total of 10 eyes in the combined group and 14 eyes in the control group had long-term follow-up data.
Table 1: Mean IOP values (mmHg) by visit.
Baseline 12 months 12 months wo. 48 months 48 months wo.
Treatment group (SD) 17,8 (2,7) 14,7 (1,3) 16,1 (2) 15,9 (2,3) 17,5 (2,3)
Control group (SD) 16,7 (3) 15,6 (1,1) 18,4 (3,1) 17 (2,5) 20,4 (3,2)
SD: standard deviation; wo.: washout.
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Figure 2: Mean intraocular pressure (IOP) at long-term follow-up
before and after washout of ocular hypotensive medications at long-
term follow-up (𝑝 values prior to and after washout: 0,14 in the
combined group and 0,04 in the control group).
Table 2: Ocular hypotensive medications by visit (mean values).
Baseline 12 months 48 months
Treatment group (SD) 1,9 (0,9) 0,4 (0,7) 0,5 (0,8)
Control group (SD) 1,8 (0,7) 1 (1) 0,9 (1)
SD: standard deviation.
reported between groups at 12- and 48-month follow-up.
No postoperative stent-related adverse events were observed
in these eyes through 48 months. IOP was well controlled
in both groups throughout the entire follow-up period; no
secondary surgical intervention was required to control IOP.
In this study, the implantation of the iStent combinedwith
cataract surgery resulted in a greater IOP reduction at long-
term follow-up compared to cataract surgery alone. Ocular
hypotensive medications used were reduced, both in the
combined and in the control group. The micro-bypass stent
combined with phacoemulsification constantly reduced IOP
throughout the entire study, starting from 17,8 ± 2,7mmHg at
baseline to 16,1 ± 2mmHg at 12 months and finally to 15,9 ±
2,3mmHg at 48 months. Mean IOP in patients with cataract
and POAG treated with phacoemulsification alone, increased
at follow-up visits after washout. At long-term follow-up after
washout, IOP in the control group was significantly greater
than at baseline (20,4 ± 3,2mmHg versus 16,7 ± 3mmHg, 𝑝
= 0,002) and a 14,2% difference compared to the combined
group was reported, which was statistically significant (17,5 ±
2,3mmHg in the combined group versus 20,4 ± 3,2mmHg in
the control group, 𝑝 = 0,02). The results show how the iStent
implantation combined with cataract surgery maintains its
efficacy in lowering IOP in the long term, as reported in
previous studies [6–9].Mean IOP in the control group tended
to rise at 48-month follow-up in our study.This data suggests
a loss of efficacy with time for phacoemulsification alone,
as previously reported in other studies [6–10]. The decrease
in the number of glaucoma medications in our study is
similar in both groups (1,4 ± 0,8 the difference observed in
the combined group versus 0,9 ± 1 in the control group).
A similar reduction is observed in other studies [6, 8, 10].
The reduction in the number of medications for chronic
use in POAG remains a fundamental question with a view
to improve patients compliance and to reduce conjunctival
inflammation, preserve patients ocular surface integrity, and
prevent from reduction in the success rate of subsequent
trabeculectomy [11, 12]. With regard to safety, no adverse
events related to the stent implantation were observed.
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4. Conclusions
There are a number of strengths in this study. The length of
its follow-up is certainly one of them, being one of the longest
to be reported in literature to our knowledge [10]. More-
over, the patients’ cohort included in the study presented
with an increasingly common situation—primary open-angle
glaucoma—encountered concomitantly with cataract. Our
results are a measure of effectiveness more than a measure
of efficacy.
Our study is not without limitations. After the first 12
months patientswere referred back to their ophthalmologists,
so IOP lowering medications were not prescribed based on a
standardized protocol.This biasmight be a reason for the lack
of statistical significance in themean number of medications.
This is also why the results obtained after washout should be
considered more significant. Finally, the number of patients
evaluated at follow-upwas small, with 10 eyes in the treatment
group and 14 eyes in the control group. Our results need
confirmation in larger randomized controlled clinical trials.
In conclusion, patients having a combined cataract
surgery with iStent implantation maintained low IOP levels
after 48 months of follow-up. Cataract surgery alone showed
a loss of efficacy in controlling IOPover time. Both treatments
reduced the number of ocular hypotensive medications
prescribed.
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